Immunization Program

TO: Health Care Providers
FROM: Mick Bolduc  
Vaccine Coordinator-Connecticut Vaccine Program (CVP)
DATE: June 30, 2016
SUBJECT: Live Attenuated Influenza Vaccine (LAIV)

The primary purpose of this communication is to update you on CVP influenza vaccine supply for the upcoming 2016-17 influenza season in light of recent recommendations concerning LAIV (FluMist®).

Live Attenuated Influenza Vaccine (FluMist®)
The CDC’s Advisory Council on Immunization Practices (ACIP) has issued an interim recommendation that Live Attenuated Influenza Vaccine (LAIV) should not be used during the 2016-17 flu season based on data showing poor effectiveness of LAIV during recent influenza seasons.

Based on manufacturer projections, health officials expect that the supply of Inactivated Influenza Vaccine (IIV) will be sufficient to meet any increase in demand due to these new recommendations, though providers may need to use a flu vaccine brand other than the one that they normally select. The CVP will be purchasing additional doses of influenza vaccine from several different manufacturers to make up for the loss of LAIV. We will continue to provide updates, including an updated list of influenza vaccines available through the CVP for the 2016–2017 flu season, as this information becomes available.

If you have any questions, please feel free to contact me at (860) 509-7940.

If you are an AAP member, assistance in making the transition for the upcoming flu season is also available at: http://www.aappublications.org/news/2016/06/27/FluLetter062416.